



PRESS RELEASE

Crucell Nominates Cees de Jong as Management Board Member

Leiden, The Netherlands, 11 February 2008 - Dutch biotechnology company Crucell N.V. today announced the nomination of Dr. Cees de Jong (1961) to join its Management Board. This nomination will be proposed to Crucell's shareholders at the company's AGM on May 30, 2008.

Cees de Jong joined Crucell as Chief Operating Officer in September 2007 and in that responsibility he already is part of Crucell's Management Committee, which manages the company's day-to-day operations. Crucell's Management Board is responsible for setting the company's goals, defining strategy and achieving its financial objectives. The Management Board currently consists of three members: Chief Executive Officer Dr. Ronald Brus (Chairman), Chief Scientific Officer Dr. Jaap Goudsmit and Chief Financial Officer Mr. Leonard Kruimer.

"I am very pleased that we have the opportunity to expand our Management Board with such an experienced and highly qualified senior executive", says Chief Executive Officer Ronald Brus. "Cees will strengthen the Board with his extensive management experience and his proven achievements in operational excellence. We are confident that Cees can make an important contribution to achieving Crucell's ambitious growth strategy."

Before Dr. De Jong joined Crucell, he worked at Quest International as a member of the Board. He was responsible for the Flavours Division, which he turned around from loss making to outperforming industry growth rates. Prior to Quest, he worked as Managing Director of DSM Anti-infectives. In 1989 Dr. De Jong started his career at Gist Brocades, holding a variety of roles in Business Development, Strategy and General Management. Dr. De Jong holds a Medical Degree and earned an MBA at the Erasmus University Rotterdam.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biotechnology company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6[®] production technology. The Company licenses its PER.C6[®] technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Portugal, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.



Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

Media:

Barbara Mulder
Director Corporate Communications
Tel: +31-(0)71-519 7346
press@crucell.com

Investors/Analysts:

Oya Yavuz
Director Investor Relations
Tel: +31-(0)71-519 7064
ir@crucell.com